The West Africa Centre for Innovative Research and Care (WACIRC) at KNUST on Febraury 10, 2026 signed a Memorandum of Understanding (MoU) with MicrobiotiX, South Korea, a pioneering biopharmaceutical company committed to developing innovative therapeutics for infectious diseases and addressing the growing global crisis of antibiotic resistance.
The MoU marks the official launch of a collaborative research partnership focused on combating multi-drug resistant organisms, with particular emphasis on Pseudomonas species, bacteria known to cause severe lung infections such as pneumonia, which remains a leading cause of death from infectious diseases. The collaboration will explore bacteriophage-based therapeutic approaches, representing a promising frontier in biomedical innovation.
The signing ceremony took place at the Provost’s Conference Room of the KNUST College of Health Sciences.
Speaking at the event, Prof. Christian Agyare, Provost of the College of Health Sciences, expressed the University’s enthusiasm for the partnership. He noted that the College and the University were pleased to collaborate with their Korean partners on such a novel and impactful initiative, assuring the full support of the College and the University toward the success of the project.
Dr. John Adabie Appiah, Principal Investigator of WACIRC, highlighted the urgency of the collaboration, explaining that the increasing prevalence of multi-drug resistant infections continues to threaten health outcomes globally. He emphasized that many patients lose their lives due to resistance to existing treatments, making this Ghana–South Korea collaboration between MicrobiotiX and WACIRC a crucial step in developing life‑saving therapeutic solutions.
The Korean delegation, led by Prof. Dongeun Yong, CEO of MicrobiotiX, expressed strong optimism for the partnership. He noted that the initiative is expected not only to advance biomedical research but also to strengthen long-term health research collaboration between Ghana and South Korea.
This partnership is expected to contribute significantly to the advancement of cutting-edge infectious disease research in Ghana and the West African sub-region.